Sumitomo Pharma Co., Ltd. (4506) Cash flow
Market cap
¥564.4B
P/E ratio
8.2x
Sumitomo Pharma manufactures and sells prescription pharmaceuticals globally, with specialized focus on regenerative and cell medicine through joint ventures.
| 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Depreciation & amortization | 13,780 | 14,286 | 13,058 | 12,887 | 13,976 | 17,365 | 22,673 | 38,348 | 41,263 | 37,765 | 25,562 | 20,786 |
| Cash from operations | 30,251 | 49,415 | 21,624 | 93,420 | 48,711 | 46,128 | 135,601 | 31,239 | 11,937 | -241,893 | 16,500 | 71,715 |
| Capital expenditures | -8,662 | -5,382 | -8,132 | -5,129 | -9,265 | -7,722 | -6,048 | -7,347 | -8,467 | -10,771 | -8,498 | -4,609 |
| Cash from investing | 23,447 | 15,887 | -59,729 | -16,523 | -35,049 | -312,684 | 8,875 | -18,278 | 52,419 | 33,036 | 99,754 | 22,549 |
| Payments for dividends | -7,152 | -7,152 | -7,151 | -7,944 | -11,122 | -13,106 | -11,120 | -11,126 | -11,125 | -2,792 | -3 | -2 |
| Proceeds from issuance of term debt, net | - | - | - | 35,300 | - | - | 125,000 | - | - | - | 139,487 | - |
| Repayments of term debt | -10,348 | -6,529 | -12,000 | -9,400 | -2,960 | -19,623 | -2,960 | -4,960 | -20,060 | - | -70,000 | -84,000 |
| Cash from financing | -15,725 | -42,605 | 9,881 | -29,610 | -28,645 | 231,081 | -57,215 | -21,426 | -146,817 | 77,851 | -108,836 | -91,266 |